

## Review

# Vacuolar-type proton pump ATPases: Acidification and pathological relationships

Ge-Hong Sun-Wada<sup>1</sup> and Yoh Wada<sup>2</sup>

<sup>1</sup>Faculty of Pharmaceutical Sciences, Doshisha Woman's College, Kohdo, Kyotanabe, Kyoto, Japan and <sup>2</sup>Division of Biological Science, Institute for Scientific and Industrial Research, Osaka University, Osaka, Japan

**Summary.** Vacuolar H<sup>+</sup>-translocating ATPase (V-ATPase) is a universal proton pump, and its activity is required for a variety of cell biological processes, such as membrane trafficking, receptor-mediated endocytosis, lysosomal degradation of macromolecules, osteoclastic bone resorption, and the maintenance of acid-base homeostasis by renal intercalated cells. V-ATPase is targeted to various membranes and has different compositions depending on its cellular location. Here, we focus on recent knowledge concerning the targeting mechanism of V-ATPase, a process associated with a wide spectrum of diseases. We also discuss the functions of this enzyme in macrophages and cancer cells-2 characteristic cell types with clinical importance.

**Key words:** V-ATPase, Acidification, Macrophage, Cancer

### General introduction of V-ATPase

Vacuolar H<sup>+</sup>-translocating ATPase (V-ATPase) is a ubiquitous enzyme found in various eukaryotes of the Animalia, Plantae, Fungi, and Protista kingdoms. Its function is to transport protons across membranes at the expense of ATP. As in the case of its sibling, the F-type ATP synthase, chemiosmotic energy conversion involves mechanical rotation within the enzyme complex (Hirata et al., 2003). In this respect, the F- and V-type proton

translocating ATPases are highly unique enzymes that carry out chemical, electroosmotic, and mechanical energy transductions (Futai et al., 2012). These complicated reactions are performed via the interaction between the multiple subunits. However, the 2 enzymes do not share any components with each other. Another distinctive nature of the 2 proton pumps is their physiological function: V-ATPase participates in proton transport across membranes to acidify 1 side of the membrane, even though it can perform the reverse reaction, whereas the F-type ATPase mainly functions in the production of ATP from ADP and phosphate using the chemiosmotic gradient of protons generated by the respiratory chain or photosynthesis (Hirata et al., 2000; Wada et al., 2000). However, bacterial F-ATPase participates in the regulation of proton concentration by pumping out protons from the cytosol to the cell exterior (Shibata et al., 1992), and in archaeobacteria, ATP synthesis is executed by the A-type ATPase, which closely resembles V-ATPase (Gogarten et al., 1989).

V-ATPase is a complex enzyme composed of at least 14 different subunits. The enzyme is organized into 2 main parts (Fig. 1). The V<sub>1</sub> sector is a complex that is located on the cytoplasmic side of the membrane and contains the catalytic center for ATP hydrolysis, whereas the V<sub>0</sub> sector is embedded in the membrane and is responsible for the translocation of protons from the cytoplasm to the lumen or extracellular environment. The V<sub>1</sub> sector is composed of 3 copies of A and B subunits, and a single copy of C, D, E, F, G, and H subunits. V<sub>0</sub> contains 6 different subunits. Yeast VO is composed of a, d, e, c, c' and c'', whereas higher eukaryotes contain the accessory subunits Ac45 (Jansen et al., 2010) and Ac8-9 (Kinouchi et al., 2010), but lack subunit c'. The proteolipid subunits (c, c' and c'') are highly hydrophobic and form a ring-like structure with a

*Offprint requests to:* Ge-hong Sun-Wada, Faculty of Pharmaceutical Sciences, Doshisha Woman's College, Kohdo, Kyotanabe, Kyoto 610-0395, Japan. e-mail: kwada@dwc.doshisha.ac.jp. or Yoh Wada, Division of Biological Science, Institute for Scientific and Industrial Research, Osaka University, Mihogaoka 8-1, Ibaraki, Osaka 567-0047, Japan. e-mail: yohwada@sanken.osaka-u.ac.jp


stoichiometry of 4 copies of *c* and single copies of the *c'* and *c''* subunits (Powell et al., 2000; Wang et al., 2007). In mammals, the structural gene for *c'* is not found in the genome, therefore mammalian enzymes are highly likely to be composed of the *c* (16 kDa) and *c''* (23 kDa) subunits (Sun-Wada et al., 2001). Mammalian genes and their corresponding yeast genes are summarized in Table 1. Overall, the  $V_0V_1$  complex is a very large supramolecule with an apparent molecular mass of c.a. 900 kDa. Its atomic structure has not yet been resolved, although it is the subject of active research. V-ATPase is present in relatively low abundance; therefore, its purification and crystallization appear difficult compared to the  $F_0F_1$  ATPase, which is abundantly expressed in the mitochondria of bovine hearts. Further, as we will discuss below, molecular heterogeneity, due to the presence of multiple subunit isoforms, negatively contributes to structural studies on the enzyme complex.

V-ATPase carries out rotational catalysis like the  $F_1F_0$  ATPase, whose mechanism has been extensively studied. It has been shown that the  $V_1$  subunits, other than *A* and *B*, form 2 types of stalks, peripheral and central, which connect the  $V_1$  and  $V_0$  domains. These stalks have distinct functions in the rotary mechanism by which V-ATPases couple ATP hydrolysis to proton transport. The

central stalk, comprising subunits *F* and *D*, serves as a rotor that couples the energy released from ATP hydrolysis to the rotation of a ring of proteolipid subunits in  $V_0$ . The peripheral stalks, comprising subunits *C*, *E*, *G*, *H*, and the N-terminal domain of subunit *a*, serve to prevent the rotation of the *A3B3* head during ATP hydrolysis, and therefore, serve a stator function (Forgac, 2007) (Fig. 1).

### Subcellular localization of V-ATPase: targeting signal

V-ATPase is distributed in a wide array of endomembrane systems constituting the secretory and endocytic pathways, and at the cell surface of highly differentiated cells. This subcellular distribution appears uncommon for membrane proteins; many membrane-associated proteins, in general, show rather restricted localization in subcellular organelles. We postulated that the localization of V-ATPase is, at least in part, determined by the structural variations of the enzyme complex itself (Futai et al., 2000). The yeast genome contains a single structural gene for each V-ATPase subunit, except the largest membrane spanning 100-kDa *a* subunit. The yeast *a* subunit is encoded by 2 genes,



**Fig. 1.** Structure of the V-ATPase. The V-ATPase complex is composed of a peripheral domain ( $V_1$ ), which is responsible for ATP hydrolysis, and an integral domain ( $V_0$ ), which is involved in proton translocation across the membrane. The core of the  $V_1$  domain is composed of a hexamer of alternating (*A* and *B*) subunits, which participate in ATP binding and hydrolysis. The  $V_0$  domain includes a ring of proteolipid subunits (*c*, *c'*, and *c''*) that are adjacent to subunits *a* and *e*. The  $V_1$  and  $V_0$  domains are connected by a central stalk, composed of subunits (*D* and *F*) of  $V_1$  and subunit *d* of  $V_0$ , and multiple peripheral stalks, composed of subunits *C*, *E*, *G*, *H*, and the N-terminal domain of subunit *a*. Mammalian V-ATPase contains the accessory proteins Ac45 and Ac8-9, both of which are essential for the function of the enzyme.

## Acidification and pathology

*VPH1* and *STV1*, exhibiting 54% identity in amino acid sequence, and *Vph1p* (Manolson et al., 1992) and *Stv1p* (Manolson et al., 1994) are localized to vacuoles and prevacuolar compartments (possibly the Golgi or endosomes), respectively.

In higher eukaryotes, including vertebrates and invertebrates, V-ATPases acquire more complex variations via a combination of various subunit isoforms. For instance, the mammalian  $V_0$  sector is composed of 1 of 4 isoforms of the 100-kDa *a* subunit and common *c* and *c'* subunits. In the metazoan *Paramecium* at least 17 different isoforms for the  $V_0$  *a* subunit have been identified (Wassmer et al., 2006). Like yeast proton pumps, each *a* subunit isoform exhibits rather restricted subcellular localization along the endocytic and exocytic pathways (Toyomura et al., 2000, 2003; Wassmer et al., 2006), suggesting that the  $V_0$  *a* subunit isoforms, at least in part, carry localization signals.

Most recently, Stevens and colleagues identified the localization signal of *Stv1*, which resides within a fairly large hydrophilic domain located at the N-terminal end of the protein. This is the first demonstration of a subcellular localization signal in the V-ATPases (Finnigan et al., 2012). This observation is an important step forward in terms of the pathogenic role of V-ATPase, given that some microorganisms alter their

subcellular localization of V-ATPase so that they can escape from the cytotoxic environment created by the proton pump and successfully adapt to the host cells. We will discuss this in the later part of this article. In mammals, 4 isoforms of the V-ATPase *a* subunit have been identified (Sun-Wada et al., 2003b). The *a1*, *a2*, and *a3* isoforms are ubiquitously expressed, although their cellular localizations are different (Toyomura et al., 2003). The *a4* isoform is specifically expressed in the kidney and other epithelial tissues (Oka et al., 2001; Smith et al., 2001; Kawamura et al., 2010). These *a* subunit isoforms exhibit ~50% amino acid sequence identity with each other. However, the N-terminal regions (amino acid residues 60–300) exhibit lower identity of ~40% (Toyomura et al., 2000), suggesting that the N-termini of these proteins is responsible for the diverse cellular localization of the enzyme in mammalian cells.

### Catalysis and enzymatic reaction

In addition to the 100-kDa *a* subunit of the  $V_0$  sector, the *B*, *C*, *D*, *E*, *G*, and *H* subunits constituting the  $V_1$  catalytic sector contain multiple isoforms, which exhibit tissue-specific expression profiles [for reviews, see (Sun-Wada and Wada, 2010) and (Smith et al.,

**Table 1.** Characteristics of V-ATPase subunit.

Domain		Subunit	Yeast gene	Mouse isoforms (expression)	Mouse gene	
$V_1$	Catalytic hexamer (A3B3)	A	<i>VMA1</i>		<i>Atp6A1</i>	
		B	<i>VMA2</i>	<i>B1</i> (renal, epididymis, otic) <i>B2</i> (ubiquitous)	<i>Atp6V1B1</i> <i>Atp6V1B2</i>	
	Stalks	C	<i>VMA5</i>	<i>C1</i> (ubiquitous) <i>C2-a</i> (lung) <i>C2-b</i> (lung, kidney)	<i>Atp6V1C1</i> <i>Atp6V1C2a</i> <i>AtpV1C2b</i>	
		D	<i>VMA8</i>	–	<i>Atp6V1D1</i>	
		E	<i>VMA4</i>	<i>E1</i> (testis) <i>E2</i> (ubiquitous)	<i>Atp6V1E1</i> <i>Atp6V1E2</i>	
		F	<i>VMA7</i>		<i>Atp6V1F1</i>	
		G	<i>VMA10</i>	<i>G1</i> (ubiquitous) <i>G2</i> (neural) <i>G3</i> (renal, epididymis)	<i>Atp6V1G1</i> <i>Atp6V1G2</i> <i>Atp6V1G3</i>	
		H	<i>VMA13</i>	<i>H1</i> (2 alternatively spliced isoforms found in humans)	<i>Atp6V1H1</i>	
		d	<i>VMA6</i>	<i>d1</i> (ubiquitous) <i>d2</i> (renal, epididymis)	<i>Atp6Vod1</i> <i>Atp6Vod2</i>	
	$V_0$	Proton pathway	e	<i>VMA9</i>		<i>Atp6v0e</i>
			a	<i>STV1</i> <i>VPH1</i>	<i>a1</i> (ubiquitous, synaptic vesicle localization) <i>a2</i> (ubiquitous, Golgi localization) <i>a3</i> (ubiquitous, lysosomal localization) <i>a4</i> (renal, epididymis, optic)	<i>Atp6Voa1</i> <i>Atp6Voa2</i> <i>Atp6Voa3</i> <i>Atp6Voa4</i>
			c	<i>VMA3</i>		<i>Atp6Voc</i>
c'			<i>VMA11</i>	No mammalian gene		
c''			<i>VMA16</i>		<i>Atp6Vof</i>	
Ac45			No yeast gene		<i>ATP6AP1</i>	
Ac8-9	No yeast gene	Identical to the (pro)rennin receptor	<i>ATP6AP2</i>			

2003)]. It has been shown that the V-ATPases in a particular membrane of a given cell type contain specific combinations of subunit isoforms (Sun-Wada et al., 2003a,c, 2005). These isoforms may also contribute to the subcellular localization of V-ATPases; however, only a few lines of experimental evidence have been reported to date. The isoforms confer different enzyme kinetic properties on the proton pumps. For example, the mouse *E* subunit has *E1* and *E2* isoforms, and *E2* is ubiquitously expressed in all the tissues, whereas *E1* is restricted to the testis. Interestingly, V-ATPase with *E1* decoupled the proton transport and ATP hydrolysis at 37°C, the physiological temperature in mammals, but higher than the normal temperature range for the tissue where *E1* is expressed (Sun-Wada et al., 2002). Although the physiological significance of the biochemical characteristics of V-ATPases with the *E1* isoform remains to be examined, the domain between Lys26 and Val83 of *E1*, which includes 7 residues not conserved between *E1* and *E2*, is responsible for the unique thermo-labile energy coupling properties (Hayashi et al., 2008).

### Membrane orientation

Although the tertiary structure of V-ATPase remains to be solved, the topologies of the membrane-intrinsic  $V_O$  subunits have been extensively analyzed and discussed for decades. Forgac and colleagues expressed a series of yeast *a* subunits with Cys substitutions at various positions, and treated the vacuoles with membrane-permeable and membrane-impermeable maleimide, which reacts with Cys residues. Covalent chemical modification occurs at the Cys residues accessible to the maleimide reagents. Using this biochemical strategy, they determined the membrane topology of the 100-kDa subunit of the yeast proton pump, and showed that the N-terminal part is localized to the cytosol (Toei et al., 2011). This orientation is consistent with the model that this part contains the signals for subcellular localization, and interacts with the retention/localization machinery present in the cytosol. The N-terminal region is also known to interact with cytosolic proteins such as ARF nucleotide-binding site opener (ARNO) and Arf6, underscoring the cytosolic orientation of the N-terminal domain (Hurtado-Lorenzo et al., 2006).

In contrast to the N-terminal domain, orientation of the C-terminal domain remains rather ambiguous. The hydrophobicity profiles of the primary structure for the 100-kDa subunits predict 8 or 9 possible transmembrane segments, and a rather short C-terminal domain of approximately 40 amino acid residues. The differential modification study using membrane-permeable and membrane-impermeable reagents suggests 8 transmembrane segments, thus predicting a model with the C-terminal domain facing the cytosol (Toei et al., 2011). An *a3*-GFP fusion protein was expressed in mouse cells and tissues, and the GFP fluorescence completely

matched the immunofluorescence of the *a3* subunit, suggesting that the *a3*-GFP fusion protein in the cells retained the GFP moiety. Further, most fusion proteins existed as full-length products, and essentially no degradation products or truncated proteins were found in cell extracts, despite the highly degradative nature of the lysosomal lumen (Sun-Wada et al., 2009). We therefore postulate that the C-terminus of the V-ATPase *a* subunit is highly likely to be localized to the cytosol, rather than to the lysosome/phagosome lumen where digestive enzymes are accumulated. A similar topological model has been proposed for the 100-kDa *a* subunit in other organisms, including humans and *Dictyostelium* (Clarke et al., 2002; Su et al., 2003).

By contrast, a recent study, which identified a role for the C-terminal peptide of the *a3* subunit, suggested an alternative orientation (Mouline et al., 2012). The V-ATPase *a3* subunit is also known as Tirc7, which was discovered by its involvement in T-cell activation (Utku et al., 1998). Both products, i.e., *a3* and Tirc7, are encoded by the same gene, *Tcirg1*, and the 2 products, with distinct translation initiation points, are generated by alternative splicing of the messenger RNA. Therefore, they share the same primary structures in the C-terminal half. The 40-amino acid C-terminal peptide of the *a3* subunit promotes the differentiation of macrophage-derived RAW264.7 cells into osteoclasts, when added to the culture medium (Mouline et al., 2012). This observation suggests that the C-terminal region of the *a3* subunit perceives extracellular signals for lymphocyte differentiation, therefore, it should orient toward the luminal/extracellular spaces rather than the cytosol.

Loss of the *a3* subunit produces a severe bone phenotype known as osteosclerosis, in which the bone becomes denser and fragile. Indeed, the mouse *oc* mutation, a causative factor in severe osteosclerosis, was identified as a deletion of exons 1–3 of the structural gene for the V-ATPase *a3* subunit (Scimeca et al., 2000). Li and colleagues created a targeted mutation (*Atp6i*) of exons 2–5 (Li et al., 1999). Both mutations have been reported to produce almost identical phenotypes. The part of the gene that encodes the C-terminal portion of the *a3* subunit is unaffected in these mutant alleles. Thus, the Tirc7 protein is presumably translated and sustains the differentiation of osteoclasts carrying the *oc* or *Atp6i* mutations (Mouline et al., 2012). We have reported that mice homozygous for an allele lacking the exons encoding the C-terminal region exhibit bony phenotypes identical to the *oc*- and *Atp6i*- mutant mice (Sun-Wada et al., 2009; Kawamura et al., 2010). This observation suggests that the Tirc7 C-terminal peptide is not an absolute requirement for the differentiation and maintenance of osteoclasts.

### Macrophages and V-ATPase

A unicellular organism like cellular slime mold, *Dictyostelium*, eats bacterium by phagocytosis, a specific

## Acidification and pathology

form of endocytosis. The phagocytosed bacterium is then digested in the acidic environment created by the function of V-ATPases (Clarke et al., 2010). In mammals, a professional phagocytic cell, macrophage, performs surveillance and clearing tasks to protect against pathogens. Macrophages defend against pathogens and other unfavorable materials present in tissues. When these target materials are encountered, the macrophages attach to them and internalize them by phagocytosis. After internalization, the pathogens are degraded in the endocytic apparatus called phagosomes, which finally form compartments known as phagolysosomes, in which various hydrolases are enriched. The conversion of the nascent phagosomes into mature phagolysosomes is a complex process involving highly dynamic material exchange between the plasma membrane and the early and late endosomes as well as lysosomes. The endoplasmic reticulum (ER) may also participate in the assembly of phagosomes (Gagnon et al., 2002; Hatsuzawa et al., 2006), although this view has been under debate (Touret et al., 2005a,b).

One of the characteristics of this phagosome maturation is the gradual decrease in the luminal pH due to the active transport of protons from the cytosol to the lumen. The proton-rich environment in the maturing phagosome supplies the substrate for reactive oxygen species generation by NADPH oxidase. Further, the acidic interior provides a suitable chemical environment for multiple hydrolases. Like in *Dictyostelium*, this acidification of mammalian phagosomes is mediated by V-ATPase.

From the bacterial perspective, the maturation of phagosomes, including the recruitment of V-ATPase, is life threatening. It has been shown that pathogenic microorganisms prevent the recruitment of V-ATPase to phagosomes, where they reside. *Legionella pneumophila* establishes intracellular infection in macrophages (Xu et al., 2010). The bacterium secretes a specific subset of proteins to establish its intracellular habitat. SidK, a protein recently identified by screening yeast cells for mutations that phenocopied V-ATPase deficiency, has been shown to be a direct inhibitor of the V-ATPase complex. SidK binds to the A subunit of V-ATPase, a key component of the V1 sector, and prevents phagosomal acidification by inhibiting ATP hydrolysis. In addition to this inhibition of V-ATPase enzymatic activity, the host subcellular architecture is modulated at various levels by other proteins secreted by the internalized bacterium. For example, SidM affects the GTP cycles of rab1, a small GTP-binding protein that is normally a resident of the ER, and recruits it to the phagosome membrane (Muller et al., 2010, 2012). Similarly, other bacterial factors are known to modify the rab1 small GTPase by adenylation or phosphocholination and alter its GDP/GTP cycle (Neunuebel et al., 2011; Tan and Luo, 2011). These alterations in the function and localization of the rab protein result in a loss of phagosomal signatures,

including acidification, as well as proteolytic activity from the bacterium-containing phagosomes.

*Mycobacterium*, which is a clinically highly important pathogenic microorganism, prevents the recruitment of V-ATPase to the phagosomes, where they have settled. Although this interesting strategy was discovered decades ago, the underlying molecular mechanism remains largely unknown. The mechanism may involve the inhibition of the phagosome/lysosome interaction, which inevitably prevents the bacterium-containing phagosomes from acquiring V-ATPases from lysosomes or other sources, or the selective exclusion of V-ATPase from the phagosomes. Either way, the phagosomes are devoid of the proton pump for luminal acidification.

The defective acidification of phagosomes allows the bacteria to avoid being killed, and to even proliferate in the “host” cells. Therefore, the understanding of V-ATPase dynamics in the immune system is essential from a clinical perspective. However, our knowledge of how V-ATPase is specifically targeted in the cells, and how the invaders modify this host cell mechanism, is still limited.

Even for non-pathogenic bacteria and other substances, the mechanisms by which phagosomes acquire V-ATPases from other subcellular compartments are not fully understood. This is partly due to the lack of appropriate experimental tools to detect the V-ATPase complex. Phagocytosis, like endocytosis and exocytosis, is composed of multiple steps involving membrane budding, translocation, and fusion. Furthermore, the interactions between the different membranes are mediated by multiple mechanisms, including vesicle-mediated transport, formation of membrane tubules, and engulfment of different compartments. These processes are quite dynamic, and the transitional structures may be highly sensitive to physicochemical fixation. Therefore, conventional microscopic observations are difficult. In addition, fixed specimens provide only static images, and the time sequences of the events have to be reconstructed from the acquired stacks of images. The recent advances using fluorescent proteins and synthetic fluorophore techniques have entirely changed this situation and have provided critical insights into the fundamental nature of the endocytic and exocytic pathways. However, studies on phagocytosis have not immediately received such benefits. Expression of fluorescently tagged molecules requires the introduction of genetic material into cells, and most phagocytic cells are highly resistant to such genetic manipulation. Even if this intrinsic problem is solved by strategies such as the use of macrophage-like cell lines and lentivirus-mediated transfection, ectopic expression of the intrinsic membrane components of V-ATPase may cause cell death. We have attempted to introduce various expression vectors into several cell lines, including the most popular HEK293 and HeLa cells; however, these efforts were unsuccessful, most likely due to potential

toxicity of the ectopically expressed V-ATPase subunits, particularly those of the membrane-embedded  $V_O$  sector, including the *a* isoforms, *c* (16-kDa components), and *c''* (23-kDa components) subunits (our unpublished observations).

To circumvent these problems, we attempted to express a GFP-tagged ATPase under the most physiological condition, namely, from its authentic locus. We modified the mouse *Tcirg1* locus encoding the *a3* subunit, which is the major *a* subunit found on phagolysosomal membranes, to produce an *a3*-GFP fusion protein via ES-cell mediated gene targeting (Sun-Wada et al., 2009; Sakurai et al., 2012).

Using this method, we were able to selectively detect the V-ATPase with the *a3* subunit isoform, and perform live-cell imaging of the dynamics of the *a3* subunit (Fig. 2, movies 1 and 2). It is noteworthy that *a3* GFP-mice are a source of a variety of differentiated cells and tissues for live imaging of *a3*-expressing cells, thus providing a valuable tool to dissect the physiology and dynamics of the vacuolar pump in highly specialized functions (Sun-Wada et al., 2007, Kikuta et al., 2013). However, although current technical improvements provide highly efficient and labor-saving means for creating knockout and knockout mice, such reverse genetic approaches are practically time-consuming. It is noteworthy that Saw et al. reported the successful expression of GFP-tagged *a1* and *a2* in pheochromocytoma-derived PC12 cells using a lentiviral expression vector (Saw et al., 2011), showing that expression of the  $V_O$  subunits is possible at least in some cell lines, which will provide a good experimental system to explore the mechanisms underlying the localization as well as the function of the enzyme.

Interestingly, accumulating evidence indicates that V-ATPase is, at least transiently, in proximity to membrane trafficking machinery, such as SNAREs, rab GTP-binding proteins, etc. An interaction between V-ATPase and SNARE proteins has been reported in *Drosophila* neurons and kidney epithelium (Banerjee et al., 1999; Hiesinger et al., 2005). Furthermore, we have recently shown that SNARE, the well-known fusion machinery in membrane trafficking, directly interacts with V-ATPase in macrophages. It is noteworthy that V-ATPase is required for the efficient secretion of insulin-containing secretory granules from pancreatic  $\beta$ -cells, indicating that V-ATPase has a definite role in

membrane fusion (Sun-Wada et al., 2006). Similar observations have been made in other tissues and species (Hiesinger et al., 2005). Microglia are residents of the central nervous system with active phagocytic activity. They are responsible for protecting the central nervous system (CNS) from infectious pathogens, and further, they participate in the maintenance/development of the CNS via clearance of apoptotic neurons. Of course, the latter function is tightly regulated in order to prevent neurodegenerative disorders. Peri and Nusslein undertook live imaging of the V-ATPase *a* subunit in the zebrafish CNS to reveal the function of V-ATPase-containing microglia. They found that inhibition of the V-ATPase *a1* subunit by a morpholino-based approach severely affected phagocytosis. However, the acidification of the microglial phagosomes remained nearly normal (Peri and Nusslein-Volhard, 2008). This interesting observation suggests that the *a1* subunit is not a prerequisite for phagosomal acidification, probably due to compensation by other *a* subunit isoforms or another acidification system present on the plasma membrane, although phagocytic membrane dynamics is highly dependent on the presence of the *a1* subunit. Thus, it has once again been shown that V-ATPase function is intimately involved in the fusion of different membranes during phagocytosis. Most recently, Wong et al. reported that the V-ATPase H subunit and the Vps33B protein are targets of the Mycobacterium protein phosphatase A (PtpA), whose function is indispensable for avoiding phagosomal killing. Importantly, Vps33B and the V-ATPase subunit were co-immunoprecipitated from macrophage cell lysates, indicating that both proteins are components of a large complex (Wong et al., 2011).

The osteoclast is also a macrophage-derived cell specialized for bone resorption. It attaches to the bone surface to form a microenvironment called lacuna, actively secretes protons into the lacuna to resolve the bone matrix, and phagocytoses the resolved materials and proteins. This extracellular acidification is dependent on the V-ATPase with the *a3* isoform (Kikuta et al., 2013). Genetic loss of *TCIRG1* results in a complication known as autosomal recessive osteoporosis (ARO) (also known as stone bone or marble bone disease) due to severe impairment in osteoclast function. Interestingly, the differentiation of osteoclasts itself is not affected by the loss of the *a3* subunit. In addition to


---

**Movie 1.** Macrophages homozygous for *Tcirg1<sup>loxGFP</sup>* were cultured in a glass-bottom dish and stained with LysoTracker, as described in Figure 2. The time sequence of the live images was recorded under a wide-field fluorescence microscope, Leica-ASMDW. The Nomarski, *a3*-GFP signal (green), LysoTracker signal (red), and the merged images for GFP and LysoTracker are shown. See the movie in [http://www.hh.um.es/pdf/Movies/11\\_302/movie\\_1.mov](http://www.hh.um.es/pdf/Movies/11_302/movie_1.mov)

**Movie 2.** Splenocytes were isolated from mice homozygous for *Tcirg1<sup>loxGFP</sup>* and cultured in a glass-bottom dish. After pulse labeling with Texas-Red transferrin (25 ng/mL for 15 min), the cells were observed with Leica-ASMDW. In live splenocytes, *a3*-GFP (green) is associated with tubular structures extending from the perinuclear region toward the cell periphery. Texas-Red transferrin (red), a marker for early and/or recycling endosomes, moves along tubular structures. See the movie in [http://www.hh.um.es/pdf/Movies/11\\_302/movie\\_2.mov](http://www.hh.um.es/pdf/Movies/11_302/movie_2.mov)

the bone pathology, loss of *a3* causes multiple complications in immune function and the sense organs, like blindness and deafness; however, the mechanism is not fully understood (Li et al., 1999; Kornak et al., 2000; Kawamura et al., 2010).

Many of the ARO mutations in *TCIRG1* occur in regulatory motifs or splice sites, or result in large deletions or truncations; however, the recessive missense mutation R444L results in a particularly malignant form of infantile osteopetrosis, which is lethal in infancy or



**Fig. 2.** Live imaging of macrophages expressing the *a3*-GFP fusion protein. Macrophages homozygous for *Tcirg1<sup>flloxGFP</sup>* were isolated and cultured in a glass-bottom dish placed on a microscope stage in a climate chamber (5% CO<sub>2</sub> atmosphere, 37°C). The medium was replaced with one containing 1  $\mu$ M LysoTracker, a fluorescent dye that accumulates in the lumen of acidic compartments. *a3*-GFP signals are detected on the membranes of tubular structures (B), and the LysoTracker signal (C) accumulates in *a3*-GFP-positive compartments. The merged image is shown in D. Bar: 10  $\mu$ m.

early childhood. Manolson and colleagues have examined the effect of a homologous mutation (R445L) in the mouse and found that the mutant *a3* localized to the ER instead of lysosomes, and its oligosaccharide moiety was misprocessed. In addition, the mutant *a3* is degraded at an increased rate (Bhargava et al., 2012).

Recently, Aubin and colleagues performed an N-ethyl-N-nitrosourea (ENU) screen and identified a dominant missense mutation (R740S) in *Tcirg1* that causes high bone density (Ochotny et al., 2011). R740S, which is dominant negative for proton pumping and bone resorption, also uncouples proton pumping from ATP hydrolysis but has no effect on ruffled border formation or polarization of osteoclasts, suggesting again that the  $V_O$  complex has proton-pumping-independent functions in mammalian cells.

### V-ATPase and cancer cells

The function of V-ATPase in extracellular acidification is also implicated in cancer metastasis. In a pioneering study in this context, Sennoue et al. found that tumor cells exhibit upregulated proton extrusion, which is mediated by V-ATPase localized at the plasma membrane. This extracellular acidification enables the cells to survive in a hypoxic environment by maintaining the cytosolic pH neutral, and simultaneously creates an acidic extracellular microenvironment (Sennoue et al., 2004). They found that the metastatic potential of cancer cells correlated with the activity of the cell surface V-ATPase. During cancer development, the carcinoma detaches from the original site of the tumor by degrading the extracellular matrix (ECM) and cell adhesion molecules, and then moves to remote sites. During this process, epithelial-mesenchymal transition (EMT) is a major morphological cue. Although experimental models remain to be developed, the extracellular acidification during EMT is critical for releasing the carcinoma cells from the ECM and the neighboring cells, the first step in migration via the lymph and/or blood circulation. We have recently shown a positive correlation between metastatic nature and the expression levels of V-ATPase in mouse B16 melanoma sub-lines (Nishisho et al., 2011). The highly metastatic nature of melanoma, the malignant transformants of melanocytes, causes serious complications after the onset of migration from the origin, and results in poor prognosis. The high-metastatic B16-F10 melanoma cells strongly expressed the *a3* isoform V-ATPase compared to the low-metastatic B16 parental cells. Knockdown of the *a3* isoform or administration of a specific V-ATPase *a3* inhibitor reduced the bone metastasis of B16-F10. These results suggest that *a3* V-ATPase promotes distant metastasis of B16-F10 cells by creating acidic environments via proton secretion. Our results also raise the possibility that inhibition of the development of cancer-associated acidic environments by suppressing *a3* V-ATPase may be a novel therapeutic approach for the treatment of cancer metastasis.

The mechanisms underlying the expression, regulation, and plasma membrane targeting of V-ATPase in metastatic tumor cells remain unclear. It is highly likely that V-ATPase localized to melanosomes may be translocated to the plasma membrane, where they serve a proton-secreting function and thus confer the melanoma with a highly invasive nature. However, this may be too simple a speculation. We previously attempted to localize the V-ATPase in melanoma cells, and discovered that the most mature melanosomes lose the V-ATPase during the maturation process (Tabata et al., 2008). This observation does not rule out the possibility that even a small amount of V-ATPase in the melanosomes may be sufficient to provide the malignant melanomas with migration capability.

Gliomas, which are malignant neoplasms in the brain, are often associated with the ectopic expression of the *a4* isoform of the V-ATPase, which is normally restricted to certain types of absorbing epithelial cells in renal, cochlear, and ocular ciliary bodies. The expression of *a4* in gliomas is likely to be correlated with their invasiveness and drug resistance; however, in tissue culture cells derived from gliomas, suppression of *a4* by siRNA does not negate these parameters highly related to malignancy (Gleize et al., 2012). Further investigation is necessary to evaluate the functional importance of *a4* expression in glioma cells.

In addition to the  $V_O$  subunit, the  $V_1$  subunit may also contribute to tumor malignancy. It is reported that patients with oral squamous cell carcinoma, the most common malignancy of the oral cavity, exhibited significantly high *ATP6VIC1* expression in their jugal mucosa. A statistically significant relationship, characterized by an increasing gradient, was also observed between *ATP6VIC1* levels and tumor stage (Perez-Sayans et al., 2010).

It is reported that patients with tuberous sclerosis or tuberous sclerosis complex (TSC), a syndrome that causes the growth of non-malignant tumors in the brain and in other vital organs, such as the kidneys, heart, eyes, lungs, and skin, express melanocytic markers such as HMB45 and MelanA in non-melanoma tumors (Martignoni et al., 2008). TSC arises from mutations in either the *TSC1* or *TSC2* gene, resulting in constitutive activation of mTORC1 (mammalian target of rapamycin complex 1), a pivotal regulator of cell growth, cell proliferation, nutrient status, and differentiation. This protein is well conserved from yeast to humans. Therefore, its dysfunction is directly associated with cancer (Efeyan and Sabatini, 2010). Bugarolas and colleagues showed that mTORC1 induces the expression of V-ATPase and other lysosomal genes via activation of an oncogenic transcription factor, TFEB (Pena-Llopis et al., 2011). On the other hand, knockdown of mTORC1 and mTORC2 induced mesenchymal-epithelial transition, and inhibition of mTOR signaling attenuated the migration and invasion of colorectal cancer (Gulhati et al., 2011). This observation suggests that pharmacological and molecular biological inhibition of

mTORC1 activity is a promising strategy for controlling cancer metastasis at multiple levels, including V-ATPase activity.

The identification of V-ATPase as an essential component of signal transduction cascades regulating cell proliferation/differentiation has highlighted its importance in cancer biology. ATP6ap2, an essential component of V-ATPase, is important for Wnt-dependent signaling, which has important regulatory circuits in multiple organs, especially in endoderm-derived tissues (Cruciat et al., 2010). mTOR signaling, which is the key regulator of the switch between cell differentiation, cell proliferation, and cell death, is mechanistically linked to the endosomal acidic environments established by V-ATPase function (Zoncu et al., 2011a,b). The observation that V-ATPase function is involved in cancer metastasis suggests that this proton pump can serve as a diagnostic and prognostic target. Furthermore, selective inhibition of V-ATPase in a spatial and/or temporal fashion may provide a new strategy to treat cancer metastasis.

**Acknowledgements.** The original work from our laboratories described in this article was carried out in collaboration with H. Tabata, N. Kawamura, M. Aoyama, and other co-workers, whose names appear in the references. This study was supported by grants-in-aids from the Ministry of Education, Culture, Science and Technology Japan, Japan Science and Technology Agency, Hayashi Foundation, and Noda Foundation (to YW and GHSW), and was supported in part by Individual Research Grants in Doshisha Women's College of Liberal Arts to GHSW.

## References

- Banerjee A., Shih T., Alexander E. A. and Schwartz J. H. (1999). SNARE proteins regulate H<sup>+</sup>-ATPase redistribution to the apical membrane in rat renal inner medullary collecting duct cells. *J. Biol. Chem.* 274, 26518-26522.
- Bhargava A., Voronov I., Wang Y., Glogauer M., Kartner N. and Manolson M.F. (2012). Osteopetrosis Mutation R444L Causes Endoplasmic Reticulum Retention and Misprocessing of Vacuolar H<sup>+</sup>-ATPase  $\alpha$ 3 Subunit. *J. Biol. Chem.* 287, 26829-26839.
- Clarke M., Kohler J., Arana Q., Liu T., Heuser J. and Gerisch G. (2002). Dynamics of the vacuolar H<sup>+</sup>-ATPase in the contractile vacuole complex and the endosomal pathway of *Dictyostelium* cells. *J. Cell Sci.* 115, 2893-2905.
- Clarke M., Maddera L., Engel U. and Gerisch G. (2010). Retrieval of the vacuolar H-ATPase from phagosomes revealed by live cell imaging. *PLoS One* 5, e8585.
- Cruciat C.M., Ohkawara B., Acebron S.P., Karaulanov E., Reinhard C., Ingelfinger D., Boutros M. and Niehrs C. (2010). Requirement of prorenin receptor and vacuolar H<sup>+</sup>-ATPase-mediated acidification for Wnt signaling. *Science* 327, 459-463.
- Efeyan A. and Sabatini D.M. (2010). mTOR and cancer: many loops in one pathway. *Curr. Opin. Cell Biol.* 22, 169-176.
- Finnigan G.C., Cronan G.E., Park H.J., Srinivasan S., Quiocho F.A. and Stevens T.H. (2012). Sorting of the yeast vacuolar-type, proton-translocating ATPase enzyme complex (V-ATPase): identification of a necessary and sufficient Golgi/endosomal retention signal in Stv1p. *J. Biol. Chem.* 287, 19487-19500.
- Forgacs M. (2007). Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. *Nat. Rev. Mol. Cell Biol.* 8, 917-929.
- Futai M., Nakanishi-Matsui M., Okamoto H., Sekiya M. and Nakamoto R.K. (2012). Rotational catalysis in proton pumping ATPases: From *E. coli* F-ATPase to mammalian V-ATPase. *Biochim. Biophys. Acta* 1817, 1711-1721.
- Futai M., Oka T., Sun-Wada G., Moriyama Y., Kanazawa H. and Wada Y. (2000). Luminal acidification of diverse organelles by V-ATPase in animal cells. *J. Exp. Biol.* 203 Pt 1, 107-116.
- Gagnon E., Duclos S., Rondeau C., Chevet E., Cameron P.H., Steele-Mortimer O., Paiement J., Bergeron J.J. and Desjardins M. (2002). Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. *Cell* 110: 119-131.
- Gleize V., Boisselier B., Marie Y., Poeta-Guyon S., Sanson M. and Morel N. (2012). The renal v-ATPase  $\alpha$ 4 subunit is expressed in specific subtypes of human gliomas. *Glia* 60, 1004-1012.
- Gogarten J.P., Kibak H., Dittrich P., Taiz L., Bowman E.J., Bowman B.J., Manolson M.F., Poole R.J., Date T., Oshima T., Konishi J., Denda K. and Yoshida M. (1989). Evolution of the vacuolar H<sup>+</sup>-ATPase: implications for the origin of eukaryotes. *Proc. Natl. Acad. Sci. USA* 86, 6661-6665.
- Gulhati P., Bowen K.A., Liu J., Stevens P.D., Rychahou P.G., Chen M., Lee E.Y., Weiss H.L., O'Connor K.L., Gao T. and Evers B.M. (2011). mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. *Cancer* 71, 3246-3256.
- Hatsuzawa K., Tamura T., Hashimoto H., Yokoya S., Miura M., Nagaya H. and Wada I. (2006). Involvement of syntaxin 18, an endoplasmic reticulum (ER)-localized SNARE protein, in ER-mediated phagocytosis. *Mol. Biol. Cell* 17, 3964-3977.
- Hayashi K., Sun-Wada G.H., Wada Y., Nakanishi-Matsui M. and Futai M. (2008). Defective assembly of a hybrid vacuolar H<sup>+</sup>-ATPase containing the mouse testis-specific E1 isoform and yeast subunits. *Biochim. Biophys. Acta* 1777, 1370-1377.
- Hiesinger P.R., Fayyazuddin A., Mehta S.Q., Rosenmund T., Schulze K.L., Zhai R.G., Verstrecken P., Cao Y., Zhou Y., Kunz J. and Bellen H.J. (2005). The V-ATPase Vo subunit  $\alpha$ 1 is required for a late step in synaptic vesicle exocytosis in *Drosophila*. *Cell* 121, 607-620.
- Hirata T., Nakamura N., Omote H., Wada Y. and Futai M. (2000). Regulation and reversibility of vacuolar H<sup>+</sup>-ATPase. *J. Biol. Chem.* 275, 386-389.
- Hirata T., Iwamoto-Kihara A., Sun-Wada G.H., Okajima T., Wada Y. and Futai M. (2003). Subunit rotation of vacuolar-type proton pumping ATPase: Relative rotation of the G as to c subunit. *J. Biol. Chem.* 278, 23714-23719.
- Hurtado-Lorenzo A., Skinner M., El Annan J., Futai M., Sun-Wada G.H., Bourgoin S., Casanova J., Wildeman A., Bechoua S., Ausiello D.A., Brown D. and Marshansky V. (2006) V-ATPase interacts with ARNO and Arf6 in early endosomes and regulates the protein degradative pathway. *Nat. Cell Biol.* 8, 124-136.
- Jansen E.J., Hafmans T.G. and Martens G.J. (2010). V-ATPase-mediated granular acidification is regulated by the V-ATPase accessory subunit Ac45 in POMC-producing cells. *Mol. Biol. Cell* 21, 3330-3339.
- Kawamura N., Tabata H., Sun-Wada G.H. and Wada Y. (2010). Optic nerve compression and retinal degeneration in *Tcirg1* mutant mice lacking the vacuolar-type H<sup>+</sup>-ATPase  $\alpha$ 3 subunit. *PLoS ONE* 5,

- e12086.
- Kikuta J., Wada Y., Kowada T., Wang Z., Sun-Wada G-H, Nishiyama I., Mizukami S., Maiya N., Yasuda H., Kumanogoh A., Kikuchi K., Germain R.N. and Ishii M. (2013). Dynamic visualization of RANKL and Th17-mediated osteoclast function. *J. Clin. Invest.* 123, 866-873.
- Kinouchi K., Ichihara A., Sano M., Sun-Wada G. H., Wada Y., Kurauchi-Mito A., Bokuda K., Narita T., Oshima Y., Sakoda M., Tamai Y., Sato H., Fukuda K. and Itoh H. (2010). The (pro)renin receptor/ATP6AP2 is essential for vacuolar H<sup>+</sup>-ATPase assembly in murine cardiomyocytes. *Circ. Res.* 107, 30-34.
- Kornak U., Schulz A., Friedrich W., Uhlhaas S., Kremens B., Voit T., Hasan C., Bode U., Jentsch T.J. and Kubisch C. (2000). Mutations in the  $\alpha 3$  subunit of the vacuolar H<sup>+</sup>-ATPase cause infantile malignant osteopetrosis. *Hum. Mol. Genet.* 9, 2059-2063.
- Li Y.P., Chen W., Liang Y., Li E. and Stashenko P. (1999). *Atp6i*-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. *Nat. Genet.* 23, 447-451.
- Manolson M., Proteau D. and Jones E. (1992). Evidence for a conserved 95-120 kDa subunit associated with and essential for activity of V-ATPases. *J. Exp. Biol.* 172, 105-112.
- Manolson M.F., Wo B., Proteau D., Taillon B.E., Roberts B.T., Hoyt M.A. and Jones E.W. (1994). STV1 gene encodes functional homologue of 95-kDa yeast vacuolar H<sup>+</sup>-ATPase subunit Vph1p. *J. Biol. Chem.* 269, 14064-14074.
- Martignoni G., Pea M., Reghellin D., Zamboni G. and Bonetti F. (2008). PECOmas: the past, the present and the future. *Virchows Arch.* 452, 119-132.
- Mouline C.C., Beranger G.E., Schmid-Antomarchi H., Quincey D., Momier D., Boukhechba F., Carle G.F., Rochet N. and Scimeca J.C. (2012). Monocytes differentiation upon treatment with a peptide corresponding to the C-terminus of activated T cell-expressed Tirc7 protein. *J. Cell Physiol.* 227, 3088-3098.
- Muller M.P., Peters H., Blumer J., Blankenfeldt W., Goody R.S. and Itzen A. (2010). The *Legionella* effector protein DrrA AMPylates the membrane traffic regulator Rab1b. *Science* 329, 946-949.
- Muller M.P., Shkumatov A.V., Oesterlin L.K., Schoebel S., Goody P.R., Goody R.S. and Itzen A. (2012). Characterization of enzymes from *Legionella pneumophila* involved in reversible adenylation of Rab1. *J. Biol. Chem.* 287, 35036-35046.
- Neunuebel M.R., Chen Y., Gaspar A.H., Backlund P.S.J., Yergey A. and Machner M.P. (2011). De-AMPylation of the small GTPase Rab1 by the pathogen *Legionella pneumophila*. *Science* 333, 453-456.
- Nishisho T., Hata K., Nakanishi M., Morita Y., Sun-Wada G.H., Wada Y., Yasui N. and Yoneda T. (2011). The  $\alpha 3$  isoform vacuolar type H<sup>+</sup>-ATPase promotes distant metastasis in the mouse B16 melanoma cells. *Mol. Cancer Res.* 9, 845-855.
- Ochotny N., Flenniken A.M., Owen C., Voronov I., Zirngibl R.A., Osborne L.R., Henderson J.E., Adamson S.L., Rossant J., Manolson M.F. and Aubin J.E. (2011). The V-ATPase  $\alpha 3$  subunit mutation R740S is dominant negative and results in osteopetrosis in mice. *J. Bone Miner. Res.* 26, 1484-1493.
- Oka T., Murata Y., Namba M., Yoshimizu T., Toyomura T., Yamamoto A., Sun-Wada G.H., Hamasaki N., Wada Y. and Futai M. (2001).  $\alpha 4$ , a unique kidney-specific isoform of mouse vacuolar H<sup>+</sup>-ATPase subunit a. *J. Biol. Chem.* 276, 40050-40054.
- Pena-Llopis S., Vega-Rubin-de-Celis S., Schwartz J.C., Wolff N.C., Tran T.A., Zou L., Xie X.J., Corey D.R. and Brugarolas J. (2011). Regulation of TFEB and V-ATPases by mTORC1. *EMBO J.* 30, 3242-3258.
- Perez-Sayans M., Reboiras-Lopez M.D., Somoza-Martin J.M., Barros-Angueira F., Diz P.G., Rey J.M. and Garcia-Garcia A. (2010). Measurement of ATP6V1C1 expression in brush cytology samples as a diagnostic and prognostic marker in oral squamous cell carcinoma. *Cancer Biol. Ther.* 9, 1057-1064.
- Peri F. and Nusslein-Volhard C. (2008). Live imaging of neuronal degradation by microglia reveals a role for v0-ATPase a1 in phagosomal fusion in vivo. *Cell* 133, 916-927.
- Powell B.W., Graham L.A. and Stevens T.H. (2000). Molecular characterization of the yeast vacuolar H<sup>+</sup>-ATPase proton pore. *J. Biol. Chem.* 275, 23654-23660.
- Sakurai C., Hashimoto H., Nakanishi H., Arai S., Wada T., Sun-Wada G. H., Wada I. and Hatsuzawa K. (2012). SNAP-23 regulates phagosome formation and maturation in macrophages. *Mol. Biol. Cell* 23, 4849-4863.
- Saw N.M., Kang S.Y., Parsaud L., Han G.A., Jiang T., Grzegorzczak K., Surkont M., Sun-Wada G.H., Wada Y., Li L. and Sugita S. (2011). Vacuolar H<sup>+</sup>-ATPase subunit Voa1 and Voa2 cooperatively regulate secretory vesicle acidification, transmitter uptake and storage. *Mol. Biol. Cell* 22, 3394-3409.
- Scimeca J.C., Franchi A., Trojani C., Parrinello H., Grosgeorge J., Robert C., Jaillon O., Poirier C., Gaudray P. and Carle G.F. (2000). The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in *osteosclerotic (oc/oc)* mutants. *Bone* 26: 207-213.
- Sennoune S.R., Bakunts K., Martinez G.M., Chua-Tuan J.L., Kebir Y., Attaya M.N. and Martinez-Zaguilan R. (2004). Vacuolar H<sup>+</sup>-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. *Am. J. Physiol. Cell Physiol.* 286, C1443-1452.
- Shibata C., Ehara T., Tomura K., Igarashi K. and Kobayashi H. (1992). Gene structure of *Enterococcus hirae* (*Streptococcus faecalis*) F1F0-ATPase, which functions as a regulator of cytoplasmic pH. *J. Bacteriol.* 174, 6117-6124.
- Smith A.N., Finberg K.E., Wagner C.A., Lifton R.P., Devonald M.A., Su Y. and Karet F.E. (2001). Molecular cloning and characterization of *Atp6n1b*: a novel fourth murine vacuolar H<sup>+</sup>-ATPase a-subunit gene. *J. Biol. Chem.* 276, 42382-42388.
- Smith A.N., Lovering R.C., Futai M., Takeda J. Brown, D. and Karet F.E. (2003). Revised nomenclature for mammalian vacuolar-type H<sup>+</sup>-ATPase subunit genes. *Mol. Cell* 12, 801-803.
- Su Y., Zhou A., Al-Lamki R.S. and Karet F.E. (2003) The a-subunit of the V-type H<sup>+</sup>-ATPase interacts with phosphofructokinase-1 in humans. *J. Biol. Chem.* 278, 20013-20018.
- Sun-Wada G.H. and Wada Y. (2010). Vacuolar-type proton pump ATPases: roles of subunit isoforms in physiology and pathology. *Histol. Histopathol.* 25, 1611-1620.
- Sun-Wada, G., Murakami, H., Nakai, H., Wada, Y. and Futai, M. (2001). Mouse *Atp6f*, the gene encoding the 23-kDa proteolipid of vacuolar proton translocating ATPase. *Gene* 274, 93-99.
- Sun-Wada G.H., Imai-Senga Y., Yamamoto A., Murata Y., Hirata T., Wada Y. and Futai M. (2002). A proton pump ATPase with testis-specific E1 subunit isoform required for acrosome acidification. *J. Biol. Chem.* 277, 18098-18105.
- Sun-Wada G.H., Murata Y., Namba M., Yamamoto A., Wada Y. and Futai M. (2003a). Mouse proton pump ATPase C subunit isoforms (C2-a and C2-b) specifically expressed in kidney and lung. *J. Biol. Chem.* 278, 44843-44851.

## Acidification and pathology

- Sun-Wada G.H., Wada Y. and Futai M. (2003b). Vacuolar H<sup>+</sup> pumping ATPases in luminal acidic organelles and extracellular compartments: common rotational mechanism and diverse physiological roles. *J. Bioenerg. Biomembr.* 35, 347-358.
- Sun-Wada G.H., Yoshimizu T., Imai-Senga Y., Wada Y. and Futai M. (2003c). Diversity of mouse proton-translocating ATPase: presence of multiple isoforms of the C, d and G subunits. *Gene* 302, 147-153.
- Sun-Wada G.H., Tabata H. and Kawamura N. (2005). Selective assembly of V-ATPase subunit isoforms in mouse kidney. *J. Bioenerg. Biomembr.* 37, 415-418.
- Sun-Wada G.H., Toyomura T., Murata Y., Yamamoto A., Futai M. and Wada Y. (2006). The  $\alpha 3$  isoform of V-ATPase regulates insulin secretion from pancreatic  $\beta$ -cells. *J. Cell. Sci.* 119, 4531-4540.
- Sun-Wada G.H., Tabata H., Kawamura N., Futai M. and Wada Y. (2007). Differential expression of  $\alpha$  subunit isoforms of the vacuolar-type proton pump ATPase in mouse endocrine tissues. *Cell Tissue Res.* 329, 239-248.
- Sun-Wada G.H., Tabata H., Kawamura N., Aoyama M. and Wada Y. (2009). Direct recruitment of H<sup>+</sup>-ATPase from lysosomes for phagosomal acidification. *J. Cell Sci.* 122, 2504-2513.
- Tabata H., Kawamura N., Sun-Wada G.H. and Wada Y. (2008). Vacuolar-type H<sup>+</sup>-ATPase with the  $\alpha 3$  isoform is the proton pump on premature melanosomes. *Cell Tissue Res.* 332, 447-460.
- Tan Y. and Luo Z.Q. (2011). *Legionella pneumophila* SidD is a deAMPyase that modifies Rab1. *Nature* 475, 506-509.
- Toei M., Toei S. and Forgac M. (2011). Definition of membrane topology and identification of residues important for transport in subunit a of the vacuolar ATPase. *J. Biol. Chem.* 286, 35176-35186.
- Touret N., Paroutis P. and Grinstein S. (2005a) The nature of the phagosomal membrane: endoplasmic reticulum versus plasmalemma. *J. Leukoc. Biol.* 77, 878-885.
- Touret N., Paroutis P., Terebiznik M., Harrison R.E., Trombetta S., Pypaert M., Chow A., Jiang A., Shaw J., Yip C., Moore H.P., van der Wel N., Houben D., Peters P.J., de Chastellier C., Mellman I. and Grinstein S. (2005b) Quantitative and dynamic assessment of the contribution of the ER to phagosome formation. *Cell* 123: 157-170.
- Toyomura T., Oka T., Yamaguchi C., Wada Y. and Futai M. (2000). Three subunit  $\alpha$  isoforms of mouse vacuolar H<sup>+</sup>-ATPase. Preferential expression of the  $\alpha 3$  isoform during osteoclast differentiation. *J. Biol. Chem.* 275, 8760-8765.
- Toyomura T., Murata Y., Yamamoto A., Oka T., Sun-Wada G.H., Wada Y. and Futai M. (2003). From lysosomes to plasma membrane: Localization of vacuolar type H<sup>+</sup>-ATPase with the  $\alpha 3$  isoform during osteoclast differentiation. *J. Biol. Chem.* 278, 22023-22030.
- Utku N., Heinemann T., Tullius S.G., Bulwin G.C., Beinke S., Blumberg R.S., Beato F., Randall J., Kojima R., Busconi L., Robertson E.S., Schulein R., Volk H.D., Milford E.L. and Gullans S.R. (1998). Prevention of acute allograft rejection by antibody targeting of *TIRC7*, a novel T cell membrane protein. *Immunity* 9, 509-518.
- Wada Y., Sambongi Y. and Futai M. (2000). Biological nano motor, ATP synthase FoF1: from catalysis to *gac10-12* subunit assembly rotation. *Biochim. Biophys. Acta* 1459: 499-505.
- Wang Y., Cipriano D.J. and Forgac M. (2007). Arrangement of subunits in the proteolipid ring of the V-ATPase. *J. Biol. Chem.* 282, 34058-34065.
- Wassmer T., Kissmehl R., Cohen J. and Plattner H. (2006) Seventeen  $\alpha$ -subunit isoforms of *Paramecium* V-ATPase provide high specialization in localization and function. *Mol. Biol. Cell* 17, 917-930.
- Wong D., Bach H., Sun J., Hmama Z. and Av-Gay Y. (2011). *Mycobacterium tuberculosis* protein tyrosine phosphatase (PtpA) excludes host vacuolar-H<sup>+</sup>-ATPase to inhibit phagosome acidification. *Proc. Natl. Acad. Sci. USA* 108, 19371-19376.
- Xu L., Shen X., Bryan A., Banga S., Swanson M.S. and Luo Z.Q. (2010). Inhibition of host vacuolar H<sup>+</sup>-ATPase activity by a *Legionella pneumophila* effector. *PLoS Pathog.* 6, e1000822.
- Zoncu R., Bar-Peled L., Efeyan A., Wang S., Sancak Y. and Sabatini D. M. (2011a). mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H-ATPase. *Science* 334, 678-683.
- Zoncu R., Efeyan A. and Sabatini D.M. (2011b). mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat. Rev. Mol. Cell Biol.* 12, 21-35.

Accepted February 6, 2012